ABT Abbott Laboratories
Data as of close
S&P 500 CompaniesDividend Aristocrats
Healthcare · Pharmaceutical Preparations
Abbott Laboratories (ABT) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $192.1 billion. Shares last traded at $110.29, 16.5% below their 52-week high. Over the past year the stock is down 11.6%. ABT trades at a price-to-earnings ratio of 30.61, above the Pharmaceutical Preparations median of 17.04. Net profit margin is 13.9%, above the peer median of -7.6%. Revenue grew 5.7% year over year. The shares yield 2.2% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-03-31. Source: SEC EDGAR/XBRL.
ABT Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $4.12B | $2.35 | 63% |
| 2024-12-31 | $3.84B | $2.19 | 29% |
| 2023-12-31 | $3.56B | $2.03 | 62% |
| 2022-12-31 | $3.31B | $1.88 | 48% |
| 2021-12-31 | $3.20B | $1.79 | 45% |
| 2020-12-31 | $2.56B | $1.43 | 57% |
| 2019-12-31 | $2.27B | $1.27 | 62% |
| 2018-12-31 | $1.97B | $1.12 | 83% |
| 2017-12-31 | $1.85B | $1.06 | 388% |
| 2016-12-31 | $1.54B | $1.04 | 110% |
| 2015-12-31 | $1.44B | $0.96 | 33% |
| 2014-12-31 | $1.34B | $0.88 | 59% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
ABT is a Dividend Aristocrat (25+ consecutive years of increases). Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $0.61 | 2026-04-29 |
| Q4 2025 (derived) | $1.01 | 2026-02-20 |
| FY 2025 | $3.72 | 2026-02-20 |
| Q3 2025 | $0.94 | 2025-10-29 |
| Q2 2025 | $1.01 | 2025-07-30 |
| Q1 2025 | $0.76 | 2025-04-30 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
ABT vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.13 | 15.35 | 31.9% | -0.28% |
| JNJ | Johnson & Johnson | $652.2B | 40.52 | 6.57 | 16.2% | -0.82% |
| ONC | Beone Medicines Ltd. | $533.8B | 814.05 | 87.09 | 10.7% | -2.48% |
| ABBV | AbbVie | $510.3B | 80.87 | 7.93 | 9.8% | -2.05% |
| MRK | Merck | $366.4B | 115.46 | 5.50 | 4.8% | -0.22% |
| ABT | Abbott Laboratories | $192.1B | 30.61 | 4.26 | 13.9% | +3.81% |
| PFE | Pfizer | $175.0B | 40.41 | 2.75 | 6.8% | +0.69% |
| VRTX | Vertex Pharmaceuticals | $144.5B | 32.80 | 11.48 | 35.0% | +1.96% |
| BMY | Bristol Myers Squibb | $128.8B | 13.94 | 2.58 | 18.5% | +0.90% |
| REGN | Regeneron Pharmaceuticals | $99.4B | 20.64 | 5.89 | 28.5% | +3.63% |
| TEVA | Teva Pharmaceutical Industries Ltd | $47.4B | 67.14 | 2.74 | 4.1% | -3.35% |
| ZTS | Zoetis | $34.4B | 13.14 | 3.61 | 27.5% | +4.35% |
| RPRX | Royalty Pharma Plc | $29.6B | 36.35 | 11.68 | 32.1% | -0.98% |
| ROIV | Roivant Sciences Ltd. | $25.9B | — | 3441.87 | — | -2.76% |
🇨🇦 Abbott Laboratories also trades on Cboe Canada as a CAD-hedged Canadian Depositary Receipt (CDR) under ABT. A CDR represents the same underlying ABT shares in Canadian dollars with the currency exposure hedged; this page tracks the US-listed shares.
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.